top of page

Auranofin Repurposing for Lung and Pancreatic Cancer: Low CA12 Expression as a Marker of Sensitivity in Patient-Derived Organoids, with Potentiated Efficacy by AKT Inhibition.

Writer's picture: Christophe DebenChristophe Deben

Updated: Apr 12, 2024

This study embarked on an ambitious journey, utilizing twenty 384-well microplates, exploring 11 drug synergy combinations, and analyzing a massive dataset of 36,960 images totalling 921 GB. This vast collection of data was instrumental in validating our proprietary Orbits image and data analysis pipeline. Remarkably, despite the enormity of the data, our analysis was completed in a staggering three hours, demonstrating not only the efficiency of our system but also its potential to handle large-scale, complex datasets in the realm of drug screening and analysis.


Our research identified a particularly effective drug combination strategy, focusing on auranofin in tandem with AKT inhibition using MK2206. Read the full story in our publication in the Journal of Experimental & Clinical Cancer Research.



Bubble plot showing the cytotoxic (red) and synergistic (large sized bubbles) interaction between MK2206 and Auranofin, selective for tumor organoids compared to normal pulmonary organoids (LU_46N, LU_51N).

Example of the effectiveness of the MK2206 - Auranofin combination strategy in pancreatic cancer organoids (PDAC_044) and absence of effect in normal pulmonary organoids (LU_46N). Magenta: Orbits label-free organoid segmentation; Green: cytotox green cell death marker.


35 views0 comments

Comments


bottom of page